Clinical Trial Update: Efficacy and Safety Study of BMN 110 for Morquio A Syndrome Patients Who Have Limited Ambulation [Phase 2]

View source ↗

Summary

Phase 2 efficacy and safety study of BMN 110 (elosulfase alfa) for Morquio A syndrome with limited ambulation was terminated, with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Morquio Syndrome
• Mucopolysaccharidosis Iva

Drugs mentioned

• BMN 110

Snippet

Sponsor: BioMarin Pharmaceutical | Conditions: Mucopolysaccharidosis IVA, Morquio A Syndrome | Phase 2 | Status: TERMINATED | Results posted: 2016-01-12